Editorial / What this is
About Sermorelin Medicine
An independent editorial board reading the sermorelin literature — what it is, what it is not, and the line we hold.
What this site is
Sermorelin Medicine is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin (GHRH(1-29)). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science — the mechanism, the GH-axis and cognition trials, and the honest limits of the adult evidence, each finding cited to its source.
What the name means
The word "medicine" in the name is editorial framing — a position this publisher occupies relative to the literature, not a claim about services this site provides. Sermorelin's history makes the word especially worth handling carefully: sermorelin acetate was once an FDA-approved pediatric medicine (NDA 020443), was withdrawn from the US market in 2008 for commercial reasons, and is now prepared by compounding pharmacies. So sermorelin genuinely was a medicine, and is studied as a research compound today.
That history is exactly why we are explicit about a distinction many sources blur: research-grade sermorelin described here is not presented as a current medicine to take. "Formerly FDA-approved, now compounded" is the accurate frame, and we keep the approved-pediatric history, the adult research, and the compounded present clearly separated rather than collapsed into a single marketing pitch.
How we read the literature
Our method is simple and consistent. Every quantitative claim — a dose, a percentage, a half-life, a P-value — is tied to a specific published study and listed on the references page. We lead with what the trials established and mark the gaps where the evidence runs thin, including the limited long-term adult data and the theoretical GH/IGF-1 caution. Where a result comes from a related analog such as tesamorelin rather than native sermorelin, we say so. We avoid product, vendor, and brand framing entirely. The aim is a sober reading board: the published record on sermorelin, organized and cited, with the honest caveats kept visible.